NEW YORK – CAR T-cell therapy developer Cargo Therapeutics earlier this week announced it will be bought by Concentra Biosciences.

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

The funds will help the firm advance copper-based radioligand therapies and imaging agents in prostate, neuroendocrine, and breast cancers.

The biotech firm eliminated the need for surgical administration in the study by using an infusion catheter system in a cardiac cath lab.

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.